Medgadget previously reported on Health Canada’s approval of the wound care imaging device, MolecuLight i:X. Canadian fluorescence image-guidance technology company MolecuLight Inc continues to reach milestones for both the company and the field of wound care. MolecuLight has now been granted CE Mark approval for the MolecuLight i:X Imaging Device, which enables the commercial distribution of this technology in the European Union. The news has been eagerly received by EU clinicians, with the product currently being debuted at the World Union of Healing Societies World Congress being held in Italy between September 25th-29th. Although the device is not currently available in the United States, US FDA de novo approval is pending.
MolecuLight i:X is a point-of-care device that provides real-time fluorescence visualization of infection-causing bacteria without the requirement for contrast agent use. The device has undergone extensive pre-clinical and clinical testing and has demonstrated safety and efficacy as a tool for wound assessment, diagnosis, and treatment guidance at the bedside. Through its research, development, and commercialization efforts, the company hopes to enable the widespread use of the device as a standard tool for wound care worldwide.
Here’s a promo video showing off the MolecuLight i:X:
Product page: MolecuLight’s i:X…
Via: MolecuLight…